Pieris AG

Company

    • Company type:
      • Research & Development
    • Year founded:
    • 2001
    • Employees (at the site):
    • 45
    • Turnover range:
    • <5m EUR
    • Products/services:
    • Pieris AG is an independent biotechnology company advancing its proprietary Anticalin® technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches. Pieris’ pipeline ranges from its lead clinical program (anti-VEGF, oncology), to multiple Anticalins in preclinical development. Pieris will commercialize Anticalin therapeutics through strategic partnerships, involving both its proprietary pipeline and its de novo drug discovery capabilities. The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan. Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures.

    • Core competencies:
    • not available

    • Language skills:
    • English
      German
    • Key Tech / section:
      • Medical Technology: Cancer diagnostics and therapy
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Laurent Audoly (Mr.)
      - Management
      - Research & development

      Stephen Yoder (Mr.)
      - Management

      Claus Schalper (Mr.)
      - Management